Nóvember 2021: Fyrsta klíníska rannsóknin á Suður-Kóreu heimaræktuðu næstu kynslóðar T-frumumeðferð með mótefnavaka viðtaka (CAR-T), sem er hönnuð til að sniðganga merki um ónæmiseftirlit, er nýlega hafin.
Kóreska háþróaða vísinda- og tæknistofnunin (KAIST) tilkynnti á miðvikudag að 1b. stigs klínísk rannsókn á CAR-T frumumeðferð þess sé nú gerð í Samsung læknastöðinni í Seúl. Rannsóknin er unnin með 10 kóreskum sjúklingum sem hafa fengið bakslag og óþolandi dreifð B-frumu eitilæxli. Markaðsréttur fyrir leiðsluna var færður frá háskólanum til fyrirtækisins Curocell, sem var stofnað af prófessor Kim Chan-hyuk. Curocell hefur umsjón með klínískri þróunaráætlun byltingarmannsins ónæmismeðferð.
In addition, a Phase 2 klínísk rannsókn involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for kímísk mótefnavaka viðtaka T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Þú gætir viljað lesa: CAR T-Cell meðferð í Kóreu
Niðurstöður rannsóknarinnar voru kynntar í grein sem birt var á netinu í októberhefti Molecular Therapy.
